ERBB2 and neoplasm: Consistently, a phase II clinical trial enrolling a total of 15 patients with HER2-mutant NSCLC showed that patients benefited from pyrotinib treatment with an objective response rate of 53.3% and a median of approximately 6.4 months elapsed before tumor progression [174].